While DCs can respond to TEVs carrying tumor antigens and damage-associated molecular patterns by maturation and migration to lymph nodes and cross-presentation of antigens to major histocompatibility complex (MHC) class I to activate CD8 T cells in earlier disease stages, their function can be disrupted by EVs as the cancer progresses [211]. This evidence concerns the gene CD8A and neoplasm.